Zyprexa Articles
New drugs lift Lilly's 2nd qtr sales 16%
20 July 2001
Pharma Resources files for generic high-dose Zyprexa
12 July 2001
Drug majors growing sales teams in Japan
8 June 2001
Zyprexa and Prozac effective together
11 May 2001
Axid cuts weight gain seen with Zyprexa
8 May 2001
B-MS to file NDA for Abilitat in 4th quarter
27 April 2001
Cipla mulls felodipine deal with Mutual
10 April 2001
Lilly working with FDA on GMP issues
9 March 2001
Lilly faces first generic challenge to Zyprexa
26 February 2001
Injectable Zyprexa backed in USA
16 February 2001
Stock Commentary - New York
15 February 2001
40%-123% US Rx price variations found
13 February 2001
Pfizer's antipsychotic ziprasidone gets approval in USA
7 February 2001
Zyprexa takes over as Eli Lilly's top seller
26 January 2001
Stock Commentary - New York
16 November 2000
AstraZeneca to look at Seroquel in bipolar
15 November 2000
Lilly wins US backing for long-term Zyprexa
15 November 2000
New products boost growth at Eli Lilly
20 October 2000
Lilly launches new form of Zyprexa
19 September 2000
Psychotherapeutics set for fast growth
11 September 2000
Lilly EMR in India violative of TRIPs?
25 July 2000
Eli Lilly's 2nd-qtr EPS increases 17%
25 July 2000
Earnings rise 18% at Eli Lilly
17 April 2000
Eli Lilly 4th qtr net income up 39%
28 January 2000
Lilly's Zyprexa backed in China
9 December 1999
Stock Commentary New York
4 November 1999
Zyprexa nears approval for mania episodes
2 November 1999
Eli Lilly suffers from poor Prozac sales
22 October 1999
NICE review of MS drugs in UK delayed
20 October 1999
Stock Commentary New York
30 September 1999
Novartis Trileptal approvable in USA; firm building broad franchise in
30 September 1999
Lilly pulls Zyprexa application for Alzheimer's dementia
9 September 1999
Eli Lilly's Evista shows efficacy in osteoporosis treatment
19 August 1999
World's top-selling drugs; 2002 forecasts
13 August 1999
Zyprexa efficacy in bipolar disorder
24 June 1999
Beyond Prozac : Lilly outlines future
14 June 1999
US doctors to justify costly antipsychotics
2 June 1999
Stock Commentary New York
29 March 1999
Future growth of the global pharmaceutical market evaluated by MSDW
23 February 1999
Lilly's German unit benefits from new drugs
12 February 1999
Risperdal Outperforms Zyprexa In US Study
6 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
FDA Rejection Of Lilly's Zyprexa A Surprise For Analysts
20 October 1998
US Setback For Zyprexa In Bipolar Disorder
8 October 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
High Hopes For HMR's Novel Antipsychotic
15 July 1998
FDA Says Pfizer's Zeldox Is "Non-Approvable"
24 June 1998
Risperdal "More Cost Effective" Than Zyprexa
15 June 1998
Zyprexa Lowers Risk Of Hyperprolactinemia
15 June 1998
US Quarterly Financial Results Round-Up
23 April 1998
Lilly's Zyprexa, Potential In Comorbid Depression?
16 April 1998
Rx Drug Sales In USA Grew 12.6% Last Year
6 April 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
Abbott Labs Withdraws Sertindole NDA
29 January 1998
Zeneca Upgraded By Goldman Sachs
27 January 1998
Israel OKs Extra Funding For New Drug Therapies
12 January 1998
Analysts Assess Outlook For US Drug Majors
8 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
New Products In 1998; A Look Ahead
6 January 1998
Zyprexa: Lilly Files For Bipolar Disorder
18 December 1997
FDA Approves Raloxifene For Osteoporosis
11 December 1997
Lundbeck Looks To Continue Strong Growth
6 November 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Mental Health Study Slams Managed Care
24 September 1997
Zeneca's Seroquel Debuts In UK For Schizophrenia
24 September 1997
Seroquel To Debut In First Market, The UK
18 September 1997
Zeneca's Seroquel Gains UK Approval, Its First
5 August 1997
Smaller US Firms' Losses Grow Due To R&D Costs
31 July 1997
New York Stock Comment
24 July 1997
Zeneca's Seroquel Nears Market Approval
16 July 1997
"Cost-Effectiveness" Of Lilly's Zyprexa
3 July 1997
Janssen Contests Lilly's Risperdal/Zyprexa Study
3 July 1997
Synthelabo's Amisulpride Nears UK Approval
26 June 1997
New York Stock Comment
30 May 1997
Strong Dollar Impact On Eli Lilly
5 May 1997
Bid To Change California Mental Illness Drug Policy
9 April 1997
Lilly Shares Drop On Bad Zyprexa News
10 March 1997
New York Stock Comment
3 March 1997
Pharma Strategies: M&A Or Technical Excellence?
3 March 1997
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
